Literature DB >> 12648577

Immunohistochemical and quantitative competitive PCR analyses of midkine and pleiotrophin expression in cervical cancer.

Hye-Sung Moon1, Won I Park, Sun Hee Sung, Eun-Ah Choi, Hye-Won Chung, Bock Hi Woo.   

Abstract

OBJECTIVE: The aim of this study was to determine midkine (MK) and pleiotrophin (PTN) expression in cervical cancer.
METHODS: Prospective study in tertiary teaching hospital. Normal and cancerous cervical tissues were obtained from healthy women (n = 19) and from patients with cervical cancer (n = 42). The expressions of MK and PTN mRNA and protein were examined by quantitative competitive PCR and by immunohistochemistry. MK and PTN mRNA and protein expressions were examined with respect to tumor stage and size.
RESULTS: The expressions of midkine and pleiotrophin mRNA in cervical cancer were higher than those in the normal cervix (MK, 175.59 +/- 63.3 vs 1.00 +/- 0.18 fmol, respectively; PTN, 3.18 +/- 1.25 vs. 0.86 +/- 0.12 fmol, respectively, P < 0.05), and their expressions were not correlated with cervical cancer stage or size of the tumor. The expressions of MK and PTN protein in cancerous tissue were higher than those in the normal cervix (P < 0.05). Moreover, the protein expression of MK, but not of PTN, correlated with tumor stage and size. The expressions of MK and PTN were not correlated with vascular density.
CONCLUSIONS: Our results suggest that increased midkine mRNA and protein expressions are associated with the carcinogenesis of cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12648577     DOI: 10.1016/s0090-8258(02)00070-7

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

1.  The clinical and prognostic significance of midkine in breast cancer patients.

Authors:  Fuguang Li; Peijun Tian; Jun Zhang; Changyuan Kou
Journal:  Tumour Biol       Date:  2015-07-10

2.  Tumor-associated macrophages increase the proportion of cancer stem cells in lymphoma by secreting pleiotrophin.

Authors:  Xia Wei; Sainan Yang; Xin Pu; Silian He; Zailin Yang; Xiaomin Sheng; Xiaoqin Meng; Xue Chen; Ling Jin; Wen Chen; Yong Zhang
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

Review 3.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

4.  Midkine mRNA is overexpressed in pancreatic cancer.

Authors:  Seiji Ohhashi; Kenoki Ohuchida; Kazuhiro Mizumoto; Takuya Egami; Jun Yu; Lin Cui; Hiroki Toma; Shunichi Takahata; Toshinaga Nabae; Masao Tanaka
Journal:  Dig Dis Sci       Date:  2008-08-21       Impact factor: 3.199

Review 5.  Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases.

Authors:  Takashi Muramatsu
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

Review 6.  Midkine: a promising molecule for drug development to treat diseases of the central nervous system.

Authors:  Takashi Muramatsu
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

7.  EMDomics: a robust and powerful method for the identification of genes differentially expressed between heterogeneous classes.

Authors:  Sheida Nabavi; Daniel Schmolze; Mayinuer Maitituoheti; Sadhika Malladi; Andrew H Beck
Journal:  Bioinformatics       Date:  2015-10-29       Impact factor: 6.937

8.  Pleiotrophin expression in astrocytic and oligodendroglial tumors and it's correlation with histological diagnosis, microvascular density, cellular proliferation and overall survival.

Authors:  Fernanda M Peria; Luciano Neder; Sueli K N Marie; Sergio Rosemberg; Sueli M Oba-Shinjo; Benedicto O Colli; Alberto A Gabbai; Suzana M F Malheiros; Marco A Zago; Rodrigo A Panepucci; Carlos A Moreira-Filho; Oswaldo K Okamoto; Carlos G Carlotti
Journal:  J Neurooncol       Date:  2007-04-19       Impact factor: 4.506

9.  Clinical significance of midkine expression in pancreatic head carcinoma.

Authors:  S Maeda; H Shinchi; H Kurahara; Y Mataki; H Noma; K Maemura; K Aridome; T Yokomine; S Natsugoe; T Aikou; S Takao
Journal:  Br J Cancer       Date:  2007-07-10       Impact factor: 7.640

10.  Midkine: a novel prognostic biomarker for cancer.

Authors:  Hirofumi Jono; Yukio Ando
Journal:  Cancers (Basel)       Date:  2010-04-20       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.